In T2DM rats with uncontrolled neuropathy, sitagliptin as add-on to insulin therapy produced neuroprotective effects and ameliorated hyperalgesia, oxidative stress, and inflammation, more than either drug alone [141]. This evidence concerns the gene INS and type 2 diabetes mellitus.